File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A phase II study of vinorelbine monotherapy in the treatment of advanced non-small cell lung cancer in elderly Chinese population

TitleA phase II study of vinorelbine monotherapy in the treatment of advanced non-small cell lung cancer in elderly Chinese population
Authors
Issue Date2007
PublisherLippincott Williams & Wilkins.
Citation
The 12th IASLC World Conference on Lung Cancer (WCLC 2007), Seoul, Korea, 2-6 September 2007. In Journal of Thoracic Oncology, 2007, v. 2 n. 8 suppl. 4, p. S675 How to Cite?
AbstractINTRODUCTION: on-small cell lung cancer (NSCLC) has accounted for more than 3,000 new cases each year in Hong Kong with 5-year survival less than 15%. Chemotherapy is currently the “gold standard” treatment for advanced disease in those relatively young (<70 years old) with good performance status. However the benefit of chemotherapy in the elderly has been limited by the concerns about toxicities, which may have ethnic differences. METHOD: A phase II single-centered open-labelled study, using vinorelbine (30mg/m2 ivi on day 1 and 8, every 3 weeks, for 6 cycles) in chemonaive elderly Chinese patients (>70 years old) with cytologically or histologically confirmed stage IIIB/IV NSCLC. RESULTS: There were 18 patients recruited (age 74 ± 3 years, 10 males, 33% never smokers) with good performance status (all in WHO 0 or 1). The majority of cases were adenocarcinomas (56%) and more than two-thirds in stage IIIB. Dose reduction was required because of myelosuppression in 9.9%. The median number of cycles administered was 4, with 6 patients managed to complete 6 cycles of chemotherapy. The objective tumour response rate was 11.1% with 33.3% stable disease. The median survival was 10 months. Significant grade 3/4 toxicities occurred in neutropenia (68%), anaemia (1%), and phlebitis (4%). There was no treatment-related death. CONCLUSION: Vinorelbine as a single agent is active in the treatment of advanced NSCLC in the elderly Chinese with acceptable toxicity profile. Future study comparing with combination chemotherapy is warranted.
Persistent Identifierhttp://hdl.handle.net/10722/101858
ISSN
2015 Impact Factor: 5.04
2015 SCImago Journal Rankings: 2.597

 

DC FieldValueLanguage
dc.contributor.authorHo, JCMen_HK
dc.contributor.authorWang, Jen_HK
dc.contributor.authorWong, Men_HK
dc.contributor.authorLam, WKen_HK
dc.date.accessioned2010-09-25T20:07:15Z-
dc.date.available2010-09-25T20:07:15Z-
dc.date.issued2007en_HK
dc.identifier.citationThe 12th IASLC World Conference on Lung Cancer (WCLC 2007), Seoul, Korea, 2-6 September 2007. In Journal of Thoracic Oncology, 2007, v. 2 n. 8 suppl. 4, p. S675en_HK
dc.identifier.issn1556-0864-
dc.identifier.urihttp://hdl.handle.net/10722/101858-
dc.description.abstractINTRODUCTION: on-small cell lung cancer (NSCLC) has accounted for more than 3,000 new cases each year in Hong Kong with 5-year survival less than 15%. Chemotherapy is currently the “gold standard” treatment for advanced disease in those relatively young (<70 years old) with good performance status. However the benefit of chemotherapy in the elderly has been limited by the concerns about toxicities, which may have ethnic differences. METHOD: A phase II single-centered open-labelled study, using vinorelbine (30mg/m2 ivi on day 1 and 8, every 3 weeks, for 6 cycles) in chemonaive elderly Chinese patients (>70 years old) with cytologically or histologically confirmed stage IIIB/IV NSCLC. RESULTS: There were 18 patients recruited (age 74 ± 3 years, 10 males, 33% never smokers) with good performance status (all in WHO 0 or 1). The majority of cases were adenocarcinomas (56%) and more than two-thirds in stage IIIB. Dose reduction was required because of myelosuppression in 9.9%. The median number of cycles administered was 4, with 6 patients managed to complete 6 cycles of chemotherapy. The objective tumour response rate was 11.1% with 33.3% stable disease. The median survival was 10 months. Significant grade 3/4 toxicities occurred in neutropenia (68%), anaemia (1%), and phlebitis (4%). There was no treatment-related death. CONCLUSION: Vinorelbine as a single agent is active in the treatment of advanced NSCLC in the elderly Chinese with acceptable toxicity profile. Future study comparing with combination chemotherapy is warranted.-
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins.-
dc.relation.ispartofJournal of Thoracic Oncologyen_HK
dc.titleA phase II study of vinorelbine monotherapy in the treatment of advanced non-small cell lung cancer in elderly Chinese populationen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailHo, JCM: jhocm@hku.hken_HK
dc.identifier.emailLam, WK: lamwk@hku.hken_HK
dc.identifier.authorityHo, JCM=rp00258en_HK
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.JTO.0000283966.29438.80-
dc.identifier.hkuros147550en_HK
dc.identifier.spageS675en_HK
dc.identifier.epageS675-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats